|
|
Neuropace Inc (NASDAQ: NPCE) |
|
Price: $14.6500
$0.24 
1.666%
|
| Day's High:
| $14.670000076293945
| Week Perf:
| 3.46 %
|
| Day's Low: |
$ 14.25 |
30 Day Perf: |
13.65 % |
| Volume (M): |
148,262 |
52 Wk High: |
$ 19.60 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$14.43 |
| Open: |
$14.41 |
52 Wk Low: |
$8.88 |
|
|
| Market Capitalization (Millions $) |
494 |
| Shares
Outstanding (Millions) |
34 |
| Employees |
209 |
| Revenues (TTM) (Millions $) |
99 |
| Net Income (TTM) (Millions $) |
-22 |
| Cash Flow (TTM) (Millions $) |
-12 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Neuropace Inc is a medical device company that specializes in developing and manufacturing neurostimulation systems for the treatment of neurological disorders. The company is known for its innovative RNS System, which stands for Responsive Neurostimulation System. This system is designed to detect and respond to abnormal electrical activity in the brain, providing therapy to patients suffering from epilepsy.
The RNS System consists of a small implantable device that is placed in the skull and connected to electrodes placed on or in the brain. It continuously monitors brain activity and delivers electrical pulses in response to abnormal patterns, helping to prevent seizures.
Neuropace Inc's RNS System is the first and only FDA-approved brain-responsive neurostimulation system for the treatment of refractory epilepsy. It offers a personalized and adaptive approach to managing seizures, with the potential to improve the quality of life for patients who are not adequately controlled by medication alone.
The company is headquartered in Mountain View, California, and operates globally, offering its neurostimulation technology to patients and healthcare professionals worldwide. Neuropace Inc is committed to further advancing the field of neuromodulation and exploring the potential of neurostimulation for the treatment of various neurological disorders.
Company Address: 455 N. Bernardo Avenue Mountain View 94043 CA
Company Phone Number: 237-2700 Stock Exchange / Ticker: NASDAQ NPCE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Announcement
Published Mon, Jun 2 2025 7:44 PM UTC
Investigative Alert: Pomerantz Law Firm Probes Potential Investor Claims Against NeuroPace, Inc. Amidst Robust Revenue GrowthIn a notable development from the financial and legal landscapes, Pomerantz LLP is initiating an investigation concerning potential claims on behalf of investors of NeuroPace, Inc. (NASDAQ: NPCE). This action reflects the firm’s commitment to safegu...
|
| Shares
Published Thu, Feb 13 2025 9:35 PM UTC
NeuroPace s Strategic Maneuvers: Navigating the Market for Epilepsy SolutionsIn a notable display of market confidence and strategic foresight, NeuroPace, Inc. a pioneering force in the development of innovative solutions for epilepsy management, announced on February 13, 2025, its intention to conduct an underwritten public offering of $65 million worth of common stock. Thi...
|
| Shares
Published Tue, Feb 18 2025 9:05 PM UTC
NeuroPace Secures $74.8 Million Through Successful Public Offering: A Strategic Move Amidst Growing Demand for Neuromodulation SolutionsOn February 18, 2025, NeuroPace, Inc. (Nasdaq: NPCE), a leader in neuromodulation therapies, announced the successful completion of its underwritten public offering of common stock, securing approximately $74.8 million in gross proceeds. Thi...
|
| Shares
Published Thu, Feb 20 2025 9:05 PM UTC
NeuroPace Completes Strategic Share Repurchase, Strengthens Market Position MOUNTAIN VIEW, Calif. Feb. 20, 2025 NeuroPace, Inc. (NASDAQ: NPCE), a cutting-edge medical device company dedicated to improving the lives of individuals living with epilepsy, has announced the successful completion of its recent initiative to repurchase 5,270,845 shares of its common stock from KC...
|
| Clinical Study
Published Mon, Nov 4 2024 9:05 PM UTC
Advancements in Neuromodulation: NeuroPace s RNS System Demonstrates Promising Outcomes in Focal Epilepsy : The advent of neuromodulation technologies has ushered in innovative therapeutic modalities for managing drug-resistant neurological disorders such as focal epilepsy. NeuroPace, a leading entity in neuromodulation, has recently submitted compelling three-year data t...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-0.65 $ |
| Revenues (TTM) |
2.93 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.6 $
|
| Book Value |
0.43 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
473,330 |
| Net
Income per Employee (TTM) |
-103,182 |
| Receivable Turnover Ratio (TTM) |
6.83 |
| Inventory Turnover Ratio (TTM) |
1.23 |
| Asset Turnover Ratio (TTM) |
0.95 |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.65 $
|
| Revenues (TTM) |
2.93 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.6 $
|
| Book Value |
0.43 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Non-US |
|
 3.17 % |
of total Revenue |
| |
On January 8 2025 the Neuropace Inc provided following guidance
nnNeuroPace Inc. Announces Preliminary Financial Projections for Q4 and Full Year 2024 along with Business Developmentsnn
NeuroPace Inc. has recently shared its preliminary unaudited financial forecasts for the fourth quarter and the entirety of 2024. According to the company's estimates, the anticipated revenue for the fourth quarter of 2024 is projected to fall within the range of $21.0 million to $21.5 million. In addition, for the full year of 2024, the total revenue is expected to be between $79.4 million and $79.9 million.
nIn summary, the company has outlined that preliminary unaudited revenues are forecasted to be approximately $21.0 million to $21.5 million for Q4 2024, and for the...
|
|
|
2.47%